GATA3 and neoplasm: All studies were retrospective, 13 were eligible for ERα comprising a total of 1616 tumour samples (1998-2020; 20 - 317 patients per cohort), 5 for ERβ consisting of 675 samples (2006-2020; 80-224 patients) and 58 for GATA3 covering a total of 4254 samples (2011-2021; 4-303 patients), as shown in Tables 1–3, respectively.